title: [Dyslipidemia and atherogenic risk in patients with rheumatoid arthritis].
abstract: BACKGROUND
  Dyslipidaemia is one of the main risk factors for atherosclerotic cardiovascular disease. Patients with rheumatoid arthritis have 2-3 times more cardiovascular risk, which is partly due to the pattern of lipids which increase the atherogenic index.
  
  
  METHODS
  A descriptive, cross-sectional, observational and prospective study was conducted on 82 patients, selected for their lipid profile. Variables associated with the disease and the drugs used were recorded. Atherogenic risk was calculated, with Chi square being used for categorical variables, and the Mann-Whitney test for the continuous ones.
  
  
  RESULTS
  The dyslipidaemia frequency was 54.9%. The most frequent age range of dyslipidaemia was between 51 and 60 years. Patients with type i obesity had a higher frequency of dyslipidaemia. Less dyslipidaemia was found with a lower rate of disease activity. Patients with cyclic citrullinated anti-peptide antibodies and positive rheumatoid factor, erythrocyte sedimentation rate>13mm or CRP>2mg/L had a higher frequency of dyslipidaemia. The mean Castelli atherogenic index was 4.36, the index of Kannel was 2.59, and triglycerides/HDL-c ratio was 3.83.Patients with dyslipidaemia showed a higher frequency of positive rheumatoid factor (P=.0008), and those patients who were taking hydroxychloroquine had a lower frequency of dyslipidaemia P=.03.
  
  
  CONCLUSIONS
  Patients with rheumatoid arthritis have a pro-atherogenic lipid profile. It is important to know this and treat it to reduce cardiovascular risk.
authors.affiliation: Servicio de Medicina Interna, Hospital Regional de Alta Especialidad Dr. Gustavo A. Rovirosa Pérez, El Recreo, Villahermosa, Tabasco, México. Electronic address: antonio_bg1986@hotmail.com.
authors.forename: José Antonio de Jesús
authors.initials: JA
authors.lastname: Batún Garrido
authors.affiliation: Servicio de Medicina Interna, Hospital Regional de Alta Especialidad Dr. Gustavo A. Rovirosa Pérez, El Recreo, Villahermosa, Tabasco, México.
authors.forename: Francisco
authors.initials: F
authors.lastname: Olán
authors.affiliation: Servicio de Medicina Interna, Hospital Regional de Alta Especialidad Dr. Gustavo A. Rovirosa Pérez, El Recreo, Villahermosa, Tabasco, México.
authors.forename: Éufrates
authors.initials: É
authors.lastname: Hernández Núñez
mesh_terms: D000368:Aged; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000503:physiopathology; D050197:Atherosclerosis / Q000453:epidemiology* / Q000209:etiology; D003430:Cross-Sectional Studies; D050171:Dyslipidemias / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000453:epidemiology; D011446:Prospective Studies; D012307:Risk Factors; D018709:Statistics, Nonparametric
chemical_list: D008055:Lipids; D006886:Hydroxychloroquine
keywords: Artritis reumatoide; Atherogenic index; Dislipidemia; Dyslipidaemia; Rheumatoid arthritis; Índice aterogénico